<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        448-212-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEZAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOCETIRIZINE DIHYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        17.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R06AE09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Levocetirizine dihydrochloride is the active ingredient of Lezal. Lezal is an antiallergic medication. For the treatment of signs of illness (symptoms) associated with: &bull; Allergic rhinitis (including persistent allergic rhinitis); &bull; Nettle rash (urticaria)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Lezal - If you are allergic to levocetirizine dihydrochloride, to cetirizine, to hydroxyzine or any of the other ingredients of this medicine (listed in section 6). - If you have a severe impairment of kidney function (severe renal failure with creatinine clearance below 10 ml/min).</p><p>&nbsp;</p><p>Warnings and precautions Talk to your doctor or pharmacist before taking Lezal. If you are likely to be unable to empty your bladder (with conditions such as spinal cord injury or enlarged prostate), please ask your doctor for advice.</p><p>If you suffer from epilepsy or are at risk of convulsions, please ask your doctor for advice as use of Lezal may cause seizure aggravation. If you are scheduled for allergy testing, ask your doctor if you should stop taking Lezal for several days before testing. This medicine may affect your allergy test results. Children The use of Lezal is not recommended for infants and children under 6 months of age. Other medicines and Lezal Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Lezal with food, drink and alcohol Caution is advised if Lezal is taken at the same time as alcohol or other agents acting on the brain. In sensitive patients, the concurrent administration of Lezal and alcohol or other agents acting on the brain may cause additional reductions in alertness and impairment of performance. Lezal can be taken with or without food. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines Some patients being treated with Lezal may experience somnolence / drowsiness, tiredness and exhaustion. Use caution when driving or operating machinery until you know how this medicine affects you. However, special tests have revealed no impairment of mental alertness, the ability to react or the ability to drive in healthy test persons after taking levocetirizine in the recommended dosage. Lezal contains methyl parahydroxybenzoate and propyl parahydroxybenzoate - Methyl parahydroxybenzoate and propyl parahydroxybenzoate may cause allergic reactions (possibly delayed), such as headache, stomach upset, and diarrhoea.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is: Adults and adolescents from the age of 12 years: 10 ml solution once daily in the evening. Special dosage instructions for specific populations: Renal and hepatic impairment Patients with impaired kidney function may be given a lower dose according to the severity of their kidney disease, and in children the dose will also be chosen on the basis of body weight; the dose will be determined by your doctor. Patients who have severe impairment of kidney function must not take Lezal. Patients who only have impaired liver function should take the usual prescribed dose. Patients who have both impaired liver and kidney function may be given a lower dose depending on the severity of the kidney disease, and in children the dose will also be chosen on the basis of body weight; the dose will be determined by your doctor. Elderly patients aged 65 years and above&nbsp;</p><p>No adaptation of the dose is necessary in elderly patients, provided their renal function is normal. Use in children Children 6 to 11 years of age: The daily recommended dose is 2.5 mg (5 mL of solution) once daily in the evening. Children 6 months to 5 years of age: The daily recommended dose is 1.25 mg (2.5mL) once daily in the evening. The administration of Lezal to infants aged less than 6 months is not recommended. How and when should you take Lezal? For oral use only. An oral syringe is supplied with the pack. The solution can be taken undiluted or diluted in a glass of water. Lezal may be taken with or without food. Handling of the oral syringe Dip the oral syringe into the bottle and draw the plunger up to the mark which corresponds to the dose in milliliters (ml) prescribed by your doctor. For use in children below 5 years of age, the daily dose of 2.5 ml is measured by the syringe inside the pack (i.e. please cautiously refer to the syringe graduation). Remove the oral syringe from the bottle and empty its contents into a spoon or into a glass of water by pressing the plunger down. The oral intake of the medicinal product should be performed right after dilution. Rinse the plunger with water after every use. How long should you take Lezal? The duration of use depends on the type, duration and course of your complaints and is determined by your physician. If you take more Lezal than you should If you take more Lezal than you should, somnolence can occur in adults. Children may initially show excitation and restlessness followed by somnolence. If you think you have taken an overdose of Lezal, please tell your doctor who will then decide what action should be taken. If you forget to take Lezal If you forget to take Lezal, or if you take a dose lower than that prescribed by your doctor, do not take a double dose to make up for a forgotten dose. Take your next dose at your normal time. If you stop taking Lezal Stopping treatment should have no negative effects. However, rarely pruritus (intense itching) may occur if you stop taking Lezal, even if those symptoms were not present before treatment initiation. The symptoms may resolve spontaneously. In some cases, the symptoms may be intense and may require treatment to be restarted. The symptoms should resolve when the treatment is restarted. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Common: may affect up to 1 in 10 people Dry mouth, headache, tiredness and somnolence/drowsiness Uncommon: may affect up to 1 in 100 people Exhaustion and abdominal pain Not known: frequency cannot be estimated from the available data Other side effects such as palpitations, increased heart rate, fits, pins and needles, dizziness, syncope, tremor, dysgeusia (distortion of the sense of taste), sensation of rotation or movement, visual disturbances, blurred vision, painful or difficult urination, inability to completely empty the bladder, oedema, pruritus (itchiness), rash, urticaria (swelling, redness and itchiness of the skin), skin eruption, shortness of breath, weight increase, muscular pain, joint pain, aggressive or agitated behavior, hallucination, depression, insomnia, recurring thoughts of or preoccupation with suicide, hepatitis, abnormal liver function, vomiting, increased appetite, nausea and diarrhoea have also been reported. Pruritus (intense itching) upon discontinuation. At the first signs of a hypersensitivity reaction, stop taking Lezal and tell your doctor. Hypersensitivity reaction symptoms may include: swelling of the mouth, tongue, face and/or throat, breathing or swallowing difficulties (chest tightness or wheezing), hives, sudden fall in blood pressure leading to collapse or shock, which may be fatal. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children. Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month. Do not store above 30&deg;C Do not use 3 months after first opening Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is levocetirizine dihydrochloride. Each 1 ml of oral solution contains 0.5 mg levocetirizine dihydrochloride. - The other ingredients are sodium acetate Anhydrous, glacial acetic acid, methyl parahydroxybenzoate , propyl parahydroxybenzoate , glycerol , Hydrogenated Glucose Syrup, saccharin sodium, tutti frutti flavour, purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The oral solution is a clear and colourless solution with tutti frutti flavour, free from foreign
matter.
Presented in 150ml amber glass bottle with white child-resistant plastic screw cap (CRC) and
tamper-evident ring.
Pack sizes: 1 amber glass bottle (150ml) per unit carton
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder and Manufacturer SPIMACO Al-Qassim pharmaceutical plant Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in October 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">لیفوسیتریزین دایھیدروكلوراید ھو المادة الفعالة في لیزال . لیزال ھو دواء مضاد للحساسیة . لعلاج علامات المرض (الأعراض) المرتبطة بما یلي: &bull; التھاب الأنف التحسسي (بما في ذلك التھاب الأنف التحسسي المستمر) ؛ &bull; طفح القراص ( الارتكاریا ).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول لیزال &minus; إذا كان لدیك حساسیة من لیفوسیتریزین دایھیدروكلوراید، السیتریزین، ھیدروكسیزاین أو أي من مكونات ھذا الدواء (المدرجة في القسم 6). &minus; إذا كان لدیك ضعف شدید في وظائف الكلى (الفشل الكلوي الحاد المصحوب بتصفیة كریاتینین أقل من 10 مل / دقیقة).</p><p dir="RTL">المحاذیر والاحتیاطات تحدث إلى طبیبك أو الصیدلي قبل تناول لیزال . إذا كنت من المحتمل أن تكون غیر قادر على إفراغ المثانة (كما فى حالات مثل إصابة الحبل الشوكي أو تضخم البروستاتا) ، یرجى سؤال طبیبك قبل تناول لیزال. إذا كنت تعاني من الصرع أو معرض لخطر التشنجات، یرجى أن تطلب من طبیبك النصیحة عند استخدامھ قد یسبب لیزال تفاقم النوبات. إذا كان من المقرر إجراء اختبار الحساسیة، فاطلب من طبیبك التوقف عن تناول لیزال لعدة مرات قبل أیام من الاختبار. قد یؤثر ھذا الدواء على نتائج اختبار الحساسیة. الأطفال لا ینصح باستخدام لیزال للرضع والأطفال دون عمر الستة أشھر. أدویة أخرى و لیزال أخبر طبیبك أو الصیدلي إذا كنت تتناول، أو تناولت مؤخرا أو قد تتناول أي أدویة أخرى. لیزال مع الطعام والشراب والكحول ینصح بالحذر إذا تم تناول لیزال في نفس الوقت مع الكحول أو أي مواد أخرى تؤثر على المخ. في المرضى الحساسة، تناول لیزال مع الكحول أو غیرھا من المواد التي تؤثر على المخ قد یسبب زیادة عدم الإحساس بالیقظة وضعف الأداء. یمكن تناول لیزال مع أو بدون طعام. الحمل والرضاعة الطبیعیة والخصوبة ً ترضعین طفلك رضاعة طبیعیة ، تعتقدین انك أو تخططین لإنجاب طفل ، اسأل أو ً ي طبیبك أو ِ إذا كنت حاملا قد تكونین حاملا الصیدلي للحصول على المشورة قبل تناول ھذا الدواء. القیادة واستخدام الآلات بعض المرضى الذین یتناولون لیزال قد یعانون من النعاس، التعب والإرھاق و الإنھاك. یرجي توخي الحذر عند القیادة أو تشغیل الآلات حتى تعرف كیف یؤثر ھذا الدواء علیك. ومع ذلك ، فقد كشفت الاختبارات المتخصصة عدم وجود ضعف في الیقظة العقلیة ، والقدرة على رد فعل أو القدرة على القیادة في الأشخاص الأصحاء بعد تناول لیفوسیتریزین في الجرعة الموصى بھا . یحتوي لیزال على میثیل باراھیدروكسي بنزوات و بروبیل باراھیدروكسي بنزوات &minus; میثیل باراھیدروكسي بنزوات وبروبیل باراھیدروكسي بنزوات قد یسببا الحساسیة (ربما یتأخر ظھورھا) ، مثل الصداع ، واضطراب المعدة ، والإسھال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ً احرص دائم ً ا على تناول ھذا الدواء تماما كما أخبرك الطبیب أو الصیدلي. تحقق مع طبیبك أو الصیدلي إذا كنت غیر متأكد.</p><p dir="RTL">الجرعة الموصى بھا ھي: البالغین والمراھقین من سن 12 سنة: 10 مل من الشراب مرة واحدة یومیا في المساء. تعلیمات الجرعة الخاصة لبعض الأشخاص: الاختلال الكلوي والكبدي یمكن إعطاء المرضى الذین یعانون من ضعف وظائف الكلى جرعة أقل وفقا لشدة أمراض الكلى، وفي الأطفال سیتم اختیار الجرعة على أساس وزن الجسم. سوف یحدد طبیبك الجرعة المناسبة. یجب على المرضى الذین یعانون من ضعف شدید في وظائف الكلى عدم تناول لیزال . المرضى الذین لدیھم ضعف في وظائف الكبد یمكنھم تناول الجرعة الموصوفة المعتادة. یمكن إعطاء المرضى الذین یعانون من ضعف وظائف الكبد والكلى جرعة أقل اعتمادا على شدة مرض الكلى، وفي الأطفال سیتم اختیار الجرعة أیضا على أساس وزن الجسم؛ سیتم تحدید الجرعة من قبل الطبیب. كبار السن من عمر 65 سنة وما فوق لا یوجد تعدیل ضروري للجرعة في المرضى المسنین، بشرط أن تكون وظائفھم الكلویة طبیعیة. الاستخدام في الأطفال مرة واحدة یومیا في المساء. ً الأطفال من سن 6 إلى 11 سنة: الجرعة الموصى بھا ھي 2.5 ملجم (5 مل شراب) مرة واحدة یومیا في المساء. ً الأطفال من عمر 6 أشھر إلى 5 سنوات: الجرعة الموصى بھا ھي 1.25 ملجم (2.5 مل شراب) لا ینصح بوصف لیزال للرضع والأطفال الصغار الذین تقل أعمارھم عن 6 أشھر. كیف ومتى یجب أن تتناول لیزال ؟ للاستخدام عن طریق الفم فقط. یتم توفیر حقنة فمویة مع العبوة. یمكن تناول الشراب مركز أو مخفف في كوب من ماء. یمكن تناول لیزال مع أو بدون طعام. التعامل مع الحقنة الفمویة اغمس الحقنة الفمویة في الزجاجة وارفع المكبس حتى العلامة التي تتوافق مع الجرعة بال مللي لتر المنصوص علیھا من قبل الطبیب. للاستخدام في الأطفال الأقل من 5 سنوات من العمر، الجرعة الیومیة 2.5 مل تقاس بواسطة الحقنة الفمویة داخل العبوة (یرجى الرجوع بحذر إلى تدریج الحقنة). اخرج الحقنة الفمویة من الزجاجة وقم بتفریغ محتویاتھا في ملعقة أو في كوب من الماء بالضغط على المكبس. یجب أن یتم تناول لیزال فورا بعد تخفیفھ بالماء. اغسل المكبس بالماء بعد كل استخدام. كم من الوقت یجب أن تستمر في تناول لیزال؟</p><p dir="RTL">تعتمد مدة الاستخدام على نوع ومدة وتطور مرضك ویتم تحدیدھا من قبل طبیبك. الجرعة الزائدة إذا كنت تناولت لیزال أكثر مما ینبغي، یمكن أن یحدث نعاس عند البالغین. قد یظھر على الأطفال في البدایة نشاط زائد وأرق یلیھا نعاس. إذا كنت تعتقد أنك تناولت جرعة زائدة من لیزال ، فالرجاء إخبار طبیبك الذي سیقرر العلاج المناسب. إذا نسیت أن تتناول لیزال إذا نسیت أن تتناول لیزال ، أو إذا كنت تناولت جرعة أقل من التي وصفھا الطبیب، لا تأخذ جرعة مضاعفة للتعویض عن جرعة منسیة. خذ الجرعة التالیة في الوقت المعتاد. إذا توقفت عن تناول لیزال في الأغلب لا یكون لوقف العلاج أعراض سلبیة. ومع ذلك، نادرا ما یحدث حكة (الحكة الشدیدة) إذا توقفت عن تناول لیزال ، حتى لو لم تكن تلك الأعراض موجودة قبل بدء العلاج. قد تختفي الأعراض من تلقاء نفسھا. في بعض الحالات ، قد تكون الأعراض شدیدة وربما تتطلب إعادة العلاج. تختفي الأعراض غالبا عند إعادة تناول العلاج. إذا كان لدیك أي أسئلة أخرى حول استخدام ھذا الدواء ، اسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جمیع الأدویة ، یمكن أن یسبب ھذا الدواء أعراضا جانبیة ، على الرغم من عدم تعرض الجمیع لھا. شائع: قد یؤثر على شخص واحد من كل 10 أشخاص جفاف الفم والصداع والإرھاق والنعاس غیر شائع: قد یؤثر على شخص واحد من كل 100 شخص إعیاء وألم في البطن غیر معروف: لا یمكن تقدیر التردد من البیانات المتاحة غیرھا من الأعراض الجانبیة مثل خفقان القلب، وزیادة معدل ضربات القلب، نوبات ،إحساس بشعور وخز دبابیس وإبر، والدوخة، إغماء ، الھزة ، خلل في حاسة التذوق ، والإحساس بالدوار أو الحركة ، اضطرابات بصریة ، عدم وضوح الرؤیة ، ً التبول المؤلم أو الصعب ، عدم القدرة على تفریغ المثانة تماما ، وذمة ، حكة ، طفح جلدي ، شري (تورم واحمرار وحكة في الجلد) ، ھیاج الجلد ، ضیق في التنفس ، زیادة الوزن ، آلام العضلات ، آلام المفاصل ، السلوك العدواني أو المھتاج ، الھلوسة ، والاكتئاب ، والأرق ، والأفكار المتكررة أو الانشغال بالانتحار ، والتھاب الكبد ، كما تم الإبلاغ عن وظائف الكبد غیر طبیعیة ، والتقیؤ ، وزیادة الشھیة والغثیان والإسھال. الحكة (الحكة الشدیدة) عند التوقف . في أول بوادر رد فعل تحسسي ، توقف عن تناول لیزال وأخبر طبیبك. أعراض رد فعل فرط الحساسیة قد تشمل: تورم الفم واللسان والوجھ و / أو الحلق ، صعوبات في التنفس أو البلع (ضیق الصدر أو أزیز) ، الارتكاریا ، وانخفاض مفاجئ في ضغط الدم مما یؤدي إلى الانھیار أو الصدمة ، والتي قد تكون قاتلة.</p><p dir="RTL">إذا تعرضت لأي أعراض جانبیة، تحدث إلى طبیبك أو الصیدلي. وھذا یشمل أي أعراض جانبیة محتملة غیر مدرجة في ھذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">یحفظ بعیدا عن متناول ونظر الأطفال. لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المدون على الملصق والكرتون بعد EXP. یشیر تاریخ انتھاء الصلاحیة إلى آخر یوم في ذلك الشھر. لا یحفظ في درجة حرارة أعلى من 30 درجة مئویة لا تتناولھ بعد مرور 3 أشھر من فتح العبوة لا تتخلص من أي أدویة عن طریق میاه الصرف الصحي أو النفایات المنزلیة. اسأل الصیدلي عن كیفیة القیام بذلك التخلص من الأدویة التي لم تعد تستخدمھا. ھذه التدابیر سوف تساعد في حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة ھي لیفوسیتریزین ثنائي ھیدروكلوراید (دایھیدروكلوراید). یحتوي كل 1 مل من المحلول الفموي على 0.5 ملجم لیفوسیتریوین دایھیدروكلوراید. - المكونات الأخرى ھي أسیتات الصودیوم اللامائیة ، حمض الخلیك الجلیدي ، المیثیل باراھیدروكسي بنزوات ، بروبیل باراھیدروكسي بنزوات ، الجلسرین ، شراب الجلوكوز المھدرج ، سكرین الصودیوم ، نكھة توتي فروتي ، والمیاه النقیة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشراب ھو محلول صافي وعدیم اللون ب نكھة توتي فروتي، خالي من الشوائب. تقدم في زجاجة 150 مل من زجاج العنبر مع غطاء بلاستیكي أبیض مقاوم للأطفال (CRC (وحلقة تمنع العبث بالزجاجة. أحجام العبوة: زجاجة عنبریة واحدة (150 مل) لكل علبة كرتون قد لا یتم تسویق جمیع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الدوائیة مصنع الأدویة بالقصیم المملكة العربیة السعودیة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة ھذه النشرة في أكتوبر 2021 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lezal 0.5 mg/ml oral solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml of oral solution contains 0.5 mg levocetirizine dihydrochloride.
Excipients with known effect
methyl parahydroxybenzoate
propyl parahydroxybenzoate
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral solution.
Clear and colourless solution with tutti frutti flavour, free from foreign matter
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lezal 0.5 mg/ml oral solution is indicated for symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) and urticaria in adults and children aged 2 years and above</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Adults and adolescents 12 years and above:</p><p>The daily recommended dose is 5 mg (10 ml of solution).once daily in the evening.</p><p><em>Elderly</em></p><p>Adjustment of the dose is recommended in elderly patients with moderate to severe renal impairment (see Renal impairment below).</p><p><em>Renal impairment</em></p><p>The dosing intervals must be individualised according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (CL<sub>cr</sub>) in ml/min is needed. The CL<sub>cr</sub>&nbsp;(ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula:</p><p><img alt="" width="431" height="66" src="data:image/png;base64,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" /></p><p>Dosing adjustments for patients with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Group</p></td><td style="vertical-align:top"><p>Creatinine clearance (ml/min)</p></td><td style="vertical-align:top"><p>Dosage and frequency</p></td></tr><tr><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&ge; 80</p></td><td style="vertical-align:top"><p>5 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>50 &ndash; 79</p></td><td style="vertical-align:top"><p>5 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>30 &ndash; 49</p></td><td style="vertical-align:top"><p>5 mg once every 2 days</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>5 mg once every 3 days</p></td></tr><tr><td style="vertical-align:top"><p>End-stage renal disease - Patients undergoing dialysis</p></td><td style="vertical-align:top"><p>&lt; 10</p></td><td style="vertical-align:top"><p>Contra-indicated</p></td></tr></tbody></table><p>In paediatric patients suffering from renal impairment, the dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient and his body weight. There are no specific data for children with renal impairment.</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of the dose is recommended (see Renal impairment above).</p><p><em>Paediatric population</em></p><p>Children 6 to 11 years of age: The daily recommended dose is 2.5 mg (5 ml of solution) once daily in the evening. Children 6 months to 5 years of age: 1.25 mg (1/2 teaspoon oral solution) [2.5mL] once daily in the evening. The recommended dose of LEZAL in patients 6 months to 11 years of age for the treatment of the symptoms of perennial allergic rhinitis and chronic idiopathic urticaria and in patients 2 to 11 years of age for the treatment of symptoms of seasonal allergic rhinitis is based on crossstudy comparisons of the systemic exposure of LEZAL in adults and pediatric patients and on the safety profile of LEZAL in both adult and pediatric patients at doses equal to or higher than the recommended dose for patients 6 months to 11 years of age.</p><p><u>Method of administration</u></p><p>An oral syringe is included in the package. The appropriate volume of oral solution should be measured with the oral syringe, and poured in a spoon or in a glass of water. The oral solution must be taken orally immediately after dilution, and may be taken with or without food.</p><p>Duration of use:</p><p>Intermittent allergic rhinitis (symptoms experienced for less than four days a week or for less than four weeks a year) has to be treated according to the disease and its history; it can be stopped once the symptoms have disappeared and can be restarted again when symptoms reappear. In case of persistent allergic rhinitis (symptoms experienced for more than four days a week or for more than four weeks a year), continuous therapy can be proposed to the patient during the period of exposure to allergens.</p><p>There is clinical experience with the use of levocetirizine for treatment periods of at least 6 months. In chronic urticaria and chronic allergic rhinitis, there is clinical experience of use of cetirizine (racemate) for up to one year.</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="https://www.medicines.org.uk/emc/images/spc/spc~19877~8~139545A.png"
 style='width:323.25pt;height:49.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/nooon/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title="spc~19877~8~139545A"/>
</v:shape><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to cetirizine, to hydroxyzine, to any other piperazine
derivatives or to any of the other excipients listed in section 6.1.
Severe renal impairment at less than 10 ml/min creatinine clearance.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Precaution is recommended with concurrent intake of alcohol (see section 4.5). Lezal contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (possibly delayed). Caution should be taken in patients with epilepsy and patients at risk of convulsion as levocetirizine may cause seizure aggravation. Lezal contains maltitol liquid Patients with rare hereditary problems of fructose intolerance should not take this medicine. Caution should be taken in patients with predisposing factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as levocetirizine may increase the risk of urinary retention. Response to allergy skin tests are inhibited by antihistamines and a wash-out period (of 3 days) is required before performing them. Pruritus may occur when levocetirizine is stopped even if those symptoms were not present before treatment initiation. The symptoms may resolve spontaneously. In some cases, the symptoms may be intense and may require treatment to be restarted. The symptoms should resolve when the treatment is restarted</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with levocetirizine (including no studies with CYP3A4 inducers); studies with the racemate compound cetirizine demonstrated that there were no clinically relevant adverse interactions (with antipyrine, azithromycin, cimetidine, diazepam, erythromycin, glipizide, ketoconazole and pseudoephedrine). A small decrease in the clearance of cetirizine (16%) was observed in a multiple dose study with theophylline (400 mg once a day); while the disposition of theophylline was not altered by concomitant cetirizine administration. In a multiple dose study of ritonavir (600 mg twice daily) and cetirizine (10 mg daily), the extent of exposure to cetirizine was increased by about 40% while the disposition of ritonavir was slightly altered (-11%) further to concomitant cetirizine administration. The extent of absorption of levocetirizine is not reduced with food, although the rate of absorption is decreased. In sensitive patients, the concurrent administration of cetirizine or levocetirizine and alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of levocetirizine in pregnant women. However, for cetirizine, the racemate of levocetirizine, a large amount of data (more than 1000 pregnancy outcomes) on pregnant women indicate no malformative or feto/neonatal toxicity. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/fetal development, parturition or postnatal development (see section 5.3). The use of levocetirizine may be considered during pregnancy, if necessary. Breast-feeding Cetirizine, the racemate of levocetirizine, has been shown to be excreted in human. Therefore, the excretion of levocetirizine in human milk is likely. Adverse reactions associated with levocetirizine may be observed in breastfed infants. Therefore, caution should be exercised when prescribing levocetirizine to lactating women. Fertility For levocetirizine no clinical data are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Comparative clinical trials have revealed no evidence that levocetirizine at the recommended dose impairs mental alertness, reactivity or the ability to drive. Nevertheless, some patients could experience somnolence, fatigue and asthenia under therapy with levocetirizine. Therefore, patients intending to drive, engage in potentially hazardous activities or operate machinery should take their response to the medicinal product into account</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical studies</p><p>Adults and adolescents above 12 years of age In therapeutic studies in women and men aged 12 to 71 years, 15.1% of the patients in the levocetirizine 5 mg group had at least one adverse drug reaction compared to 11.3% in the placebo group. 91.6 % of these adverse drug reactions were mild to moderate. In therapeutic trials, the dropout rate due to adverse events was 1.0% (9/935) with levocetirizine 5 mg and 1.8% (14/771) with placebo. Clinical therapeutic trials with levocetirizine included 935 subjects exposed to the medicinal product at the recommended dose of 5 mg daily. From this pooling, following incidence of adverse drug reactions were reported at rates of 1% or greater (common: &ge; 1/100 to &lt; 1/10) under levocetirizine 5 mg or placebo:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Preferred Term</strong></p><p><strong>(WHOART)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(n =771)</strong></p></td><td style="vertical-align:top"><p><strong>Levocetirizine 5 mg</strong></p><p><strong>(n = 935)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>25 (3.2%)</p></td><td style="vertical-align:top"><p>24 (2.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>11 (1.4%)</p></td><td style="vertical-align:top"><p>49 (5.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Mouth dry</p></td><td style="vertical-align:top"><p>12 (1.6%)</p></td><td style="vertical-align:top"><p>24 (2.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>9 (1.2%)</p></td><td style="vertical-align:top"><p>23 (2.5%)</p></td></tr></tbody></table><p>Further uncommon incidences of adverse reactions (uncommon &ge; 1/1000 to &lt; 1/100) like asthenia or abdominal pain were observed. The incidence of sedating adverse drug reactions such as somnolence, fatigue, and asthenia was altogether more common (8.1%) under levocetirizine 5 mg than under placebo (3.1%). Paediatric population Pediatric Patients 6 to 11 Months of Age A total of 45 pediatric patients 6 to 11 months of age received LEZAL 1.25 mg once daily in a two week placebo-controlled double-blind safety trial. The mean age of the patients was 9 months, 51% were Caucasian and 31% were Black. Adverse reactions that were reported in more than 1 subject (i.e. greater than or equal to 3% of subjects) aged 6 to 11 months exposed to LEZAL 1.25 mg once daily in the placebo-controlled safety trial and that were more common with LEZAL than placebo included diarrhea and constipation which were reported in 6 (13%) and 1 (4%) and 3 (7%) and 1 (4%) children in the LEZAL and placebo-treated groups, respectively. In two placebo-controlled studies in paediatric patients aged 6-11 months and aged 1 year to less than 6 years, 159 subjects were exposed to levocetirizine at the dose of 1.25 mg daily for 2 weeks and 2.5 mg daily respectively. The following incidence of adverse drug reactions was reported at rates of 1% or greater under levocetirizine or placebo.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class and Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (n=83)</strong></p></td><td style="vertical-align:top"><p><strong>Levocetirizine (n=159)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3(1.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>1(1.2%)</p></td><td style="vertical-align:top"><p>1(0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2(1.3%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>2(2.4%)</p></td><td style="vertical-align:top"><p>3(1.9%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Sleep disorder</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2(1.3%)</p></td></tr></tbody></table><p>In children aged 6-12 years double blind placebo controlled studies were performed where 243 children were exposed to 5 mg levocetirizine once daily for variable periods ranging from less than 1 week to 13 weeks. The following incidence of adverse drug reactions was reported at rates of 1% or greater under levocetirizine or placebo.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (n=240)</strong></p></td><td style="vertical-align:top"><p><strong>Levocetirizine 5mg (n=243)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>5(2.1%)</p></td><td style="vertical-align:top"><p>2(0.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>1(0.4%)</p></td><td style="vertical-align:top"><p>7(2.9%)</p></td></tr></tbody></table><p>Adverse reactions from post-marketing experience are per System Organ Class and per frequency. The frequency is defined as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data). &bull; Immune system disorders: Not known: hypersensitivity including anaphylaxis &bull; Metabolism and nutrition disorders: Not known: increased appetite &bull; Psychiatric disorders: Not known: aggression, agitation, hallucination, depression, insomnia, suicidal ideation &bull; Nervous system disorders: Not known: convulsion, paraesthesia, dizziness, syncope, tremor, dysgeusia &bull; Ear and labyrinth disorders: Not known: vertigo &bull; Eyes disorders: Not known: visual disturbances, blurred vision &bull; Cardiac disorders: Not known: palpitations, tachycardia &bull; Respiratory, thoracic and mediastinal disorders: Not known: dyspnoea &bull; Gastrointestinal disorders: Not known: nausea, vomiting, diarrhoea &bull; Hepatobiliary disorders: Not known: hepatitis &bull; Renal and urinary disorders: Not known: dysuria, urinary retention &bull; Skin and subcutaneous tissue disorders: Not known: angioneurotic oedema, fixed drug eruption, pruritus, rash, urticaria &bull; Musculoskeletal, connective tissues, and bone disorders: Not known: myalgia, arthralgia &bull; General disorders and administration site conditions: Not known: oedema &bull; Investigations:</p><p>Not known: weight increased, abnormal liver function tests Methyl parahydroxybenzoate and propyl parahydroxybenzoate may cause allergic reactions (possibly delayed). Description of selected adverse reactions After levocetirizine discontinuation, pruritus has been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Reporting hotline: 19999.</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Symptoms of overdose may include drowsiness in adults. In children, agitation and restlessness may initially occur, followed by drowsiness. Management of overdoses There is no known specific antidote to levocetirizine. Should overdose occur, symptomatic or supportive treatment is recommended. Gastric lavage may be considered shortly after ingestion of the drug. Levocetirizine is not effectively removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antihistamines for systemic use, piperazine derivatives, ATC code: R06A E09. Mechanism of action Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors. Binding studies revealed that levocetirizine has high affinity for human H1-receptors (Ki = 3.2 nmol/l). Levocetirizine has an affinity 2-fold higher than that of cetirizine (Ki = 6.3 nmol/l). Levocetirizine dissociates from H1-receptors with a half-life of 115 &plusmn; 38 min. After single administration, levocetirizine shows a receptor occupancy of 90% at 4 hours and 57% at 24 hours. Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose. Pharmacodynamic effects The pharmacodynamic activity of levocetirizine has been studied in randomised, controlled trials: In a study comparing the effects of levocetirizine 5 mg, desloratadine 5 mg, and placebo on histamine-induced wheal and flare, levocetirizine treatment resulted in significantly decreased wheal and flare formation which was highest in the first 12 hours and lasted for 24 hours, (p&lt;0.001) compared with placebo and desloratadine. The onset of action of levocetirizine 5 mg in controlling pollen-induced symptoms has been observed at 1 hour post drug intake in placebo controlled trials in the model of the allergen challenge chamber. In vitro studies (Boyden chambers and cell layers techniques) show that levocetirizine inhibits eotaxin-induced eosinophil transendothelial migration through both dermal and lung cells. A pharmacodynamic experimental study in vivo (skin chamber technique) showed three main&nbsp;inhibitory effects of levocetirizine 5 mg in the first 6 hours of pollen-induced reaction, compared with placebo in 14 adult patients: inhibition of VCAM-1 release, modulation of vascular permeability and a decrease in eosinophil recruitment. Clinical efficacy and safety The efficacy and safety of levocetirizine has been demonstrated in several double-blind, placebo controlled, clinical trials performed in adult patients suffering from seasonal allergic rhinitis, perennial allergic rhinitis, or persistent allergic rhinitis. Levocetirizine has been shown to significantly improve symptoms of allergic rhinitis, including nasal obstruction in some studies. A 6-month clinical study in 551 adult patients (including 276 levocetirizine-treated patients) suffering from persistent allergic rhinitis (symptoms present 4 days a week for at least 4 consecutive weeks) and sensitized to house dust mites and grass pollen demonstrated that levocetirizine 5 mg was clinically and statistically significantly more potent than placebo on the relief from the total symptom score of allergic rhinitis throughout the whole duration of the study, without any tachyphylaxis. During the whole duration of the study, levocetirizine significantly improved the quality of life of the patients. In a placebo-controlled clinical trial including 166 patients suffering from chronic idiopathic urticaria, 85 patients were treated with placebo and 81 patients with levocetirizine 5 mg once daily over six weeks. Treatment with levocetirizine resulted in significant decrease in pruritus severity over the first week and over the total treatment period as compared to placebo. Levocetirizine also resulted in a larger improvement of health-related quality of life as assessed by the Dermatology Life Quality Index as compared to placebo. Chronic idiopathic urticaria was studied as a model for urticarial conditions. Since histamine release is a causal factor in urticarial diseases, levocetirizine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria. ECGs did not show relevant effects of levocetirizine on QT interval. Paediatric population The paediatric safety and efficacy of levocetirizine tablets has been studied in two placebo controlled clinical trials including patients aged 6 to 12 years and suffering from seasonal and perennial allergic rhinitis, respectively. In both trials, levocetirizine significantly improved symptoms and increased health-related quality of life. In children below the age of 6 years, clinical safety has been established from several short- or long -term therapeutic studies: - one clinical trial in which 29 children 2 to 6 years of age with allergic rhinitis were treated with levocetirizine 2.5 mg daily for 4 weeks. - one clinical trial in which 45 children 6 to 11 months of age with allergic rhinitis or chronic idiopathic urticaria were treated with levocetirizine 1.25 mg daily for 2 weeks - one long-term (18 months) clinical trial in 255 levocetirizine - treated atopic subjects aged 12 to 24 months at inclusion.The safety profile was similar to that seen in the short-term studies conducted in children 1 to 5 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of levocetirizine are linear with dose- and time-independent with low inter-subject variability. The pharmacokinetic profile is the same when given as the single enantiomer or when given as cetirizine. No chiral inversion occurs during the process of absorption and elimination. Absorption Levocetirizine is rapidly and extensively absorbed following oral administration. In adults, peak plasma concentrations are achieved 0.9 h after dosing. Steady state is achieved after two days. Peak concentrations are typically 270 ng/ml and 308 ng/ml following a single and a repeated 5 mg o.d. dose, respectively. The extent of absorption is dose-independent and is not altered by food, but the peak concentration is reduced and delayed. Distribution No tissue distribution data are available in humans, neither concerning the passage of levocetirizine through the blood-brain-barrier. In rats and dogs, the highest tissue levels are found in liver and kidneys, the lowest in the CNS compartment. In humans, levocetirizine is 90% bound to plasma proteins. The distribution of levocetirizine is restrictive, as the volume of distribution is 0.4 l/kg. Biotransformation The extent of metabolism of levocetirizine in humans is less than 14% of the dose and therefore differences resulting from genetic polymorphism or concomitant intake of enzyme inhibitors are expected to be negligible. Metabolic pathways include aromatic oxidation, Nand O- dealkylation and taurine conjugation. Dealkylation pathways are primarily mediated by CYP 3A4 while aromatic oxidation involved multiple and/or unidentified CYP isoforms. Levocetirizine had no effect on the activities of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 at concentrations well above peak concentrations achieved following a 5 mg oral dose. Due to its low metabolism and absence of metabolic inhibition potential, the interaction of levocetirizine with other substances, or vice-versa, is unlikely. Elimination The plasma half-life in adults is 7.9 &plusmn; 1.9 hours. The half-life is shorter in small children. The mean apparent total body clearance in adults is 0.63 ml/min/kg. The major route of excretion of levocetirizine and metabolites is via urine, accounting for a mean of 85.4% of the dose. Excretion via faeces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion. Special population Renal impairment&nbsp;The apparent body clearance of levocetirizine is correlated to the creatinine clearance. It is therefore recommended to adjust the dosing intervals of levocetirizine, based on creatinine clearance in patients with moderate and severe renal impairment. In anuric end stage renal disease subjects, the total body clearance is decreased by approximately 80% when compared to normal subjects. The amount of levocetirizine removed during a standard 4-hour hemodialysis procedure was &lt; 10%. Paediatric population Data from a paediatric pharmacokinetic study with oral administration of a single dose of 5 mg levocetirizine in 14 children age 6 to 11 years with body weight ranging between 20 and 40 kg show that Cmax and AUC values are about 2-fold greater than that reported in healthy adult subjects in a cross-study comparison. The mean Cmax was 450 ng/ml, occurring at a mean time of 1.2 hours, weight-normalized, total body clearance was 30% greater, and the elimination half-life 24% shorter in this paediatric population than in adults. Dedicated pharmacokinetic studies have not been conducted in paediatric patients younger than 6 years of age. A retrospective population pharmacokinetic analysis was conducted in 323 subjects (181 children 1 to 5 years of age, 18 children 6 to 11 years of age, and 124 adults 18 to 55 years of age) who received single or multiple doses of levocetirizine ranging from 1.25 mg to 30 mg. Data generated from this analysis indicated that administration of 1.25 mg once daily to children 6 months to 5 years of age is expected to result in plasma concentrations similar to those of adults receiving 5 mg once daily. Elderly Limited pharmacokinetic data are available in elderly subjects. Following once daily repeat oral administration of 30 mg levocetirizine for 6 days in 9 elderly subjects (65&ndash;74 years of age), the total body clearance was approximately 33% lower compared to that in younger adults. The disposition of racemic cetirizine has been shown to be dependent on renal function rather than on age. This finding would also be applicable for levocetirizine, as levocetirizine and cetirizine are both predominantly excreted in urine. Therefore, the levocetirizine dose should be adjusted in accordance with renal function in elderly patients. Gender Pharmacokinetic results for 77 patients (40 men, 37 women) were evaluated for potential effect of gender. The half-life was slightly shorter in women (7.08 &plusmn; 1.72 hours) than in men (8.62 &plusmn; 1.84 hours); however, the body weight-adjusted oral clearance in women (0.67 &plusmn; 0.16 ml/min/kg) appears to be comparable to that in men (0.59 &plusmn; 0.12 ml/min/kg). The same daily doses and dosing intervals are applicable for men and women with normal renal function. Race The effect of race on levocetirizine has not been studied. As levocetirizine is primarily renally excreted, and there are no important racial differences in creatinine clearance, pharmacokinetic characteristics of levocetirizine are not expected to be different across races. No race-related differences in the kinetics of racemic cetirizine have been observed. Hepatic impairment The pharmacokinetics of levocetirizine in hepatically impaired subjects have not been tested. Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10&nbsp;or 20 mg of the racemic compound cetirizine as a single dose had a 50% increase in half life along with a 40% decrease in clearance compared to healthy subjects. Pharmacokinetic / pharmacodynamic relationship The action on histamine-induced skin reactions is out of phase with the plasma concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each ml of Lezal Oral Solution contains</p><table border="1" cellspacing="0" cellpadding="0" style="width:443px"><tbody><tr><td><p><strong>Name of Ingredients</strong></p></td><td><p><strong>Quantity</strong></p><p><strong>(mg)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Levocetirizine Dihydrochloride</p></td><td style="vertical-align:bottom"><p>0.500</p></td></tr><tr><td style="vertical-align:bottom"><p>Methyl Parahydroxybenzoate</p></td><td style="vertical-align:bottom"><p>0.675</p></td></tr><tr><td style="vertical-align:bottom"><p>Propyl Parahydroxybenzoate</p></td><td style="vertical-align:bottom"><p>0.075</p></td></tr><tr><td style="vertical-align:bottom"><p>Glycerol</p></td><td style="vertical-align:bottom"><p>235.200</p></td></tr><tr><td style="vertical-align:bottom"><p>Hydrogenated Glucose Syrup</p></td><td style="vertical-align:bottom"><p>400.000</p></td></tr><tr><td style="vertical-align:bottom"><p>Saccharin Sodium</p></td><td style="vertical-align:bottom"><p>0.500</p></td></tr><tr><td style="vertical-align:bottom"><p>Sodium Acetate Anhydrous</p></td><td style="vertical-align:bottom"><p>0.680</p></td></tr><tr><td style="vertical-align:bottom"><p>Glacial Acetic Acid</p></td><td style="vertical-align:bottom"><p>0.100</p></td></tr><tr><td style="vertical-align:bottom"><p>Tutti Frutti Flavour</p></td><td style="vertical-align:bottom"><p>1.500</p></td></tr><tr><td style="vertical-align:bottom"><p>Purified Water BP</p></td><td style="vertical-align:bottom"><p>360.770</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Total</strong></p></td><td style="vertical-align:bottom"><p><strong>1ml</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
After first opening: 3 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>150ml amber glass bottle with white child-resistant plastic screw cap (CRC) and tamperevident ring. Pack sizes: 1 amber glass bottle (150ml) per unit carton. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim pharmaceutical plant
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2021.

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>